Literature DB >> 15118983

Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection.

Richard K Sterling1, Mary S Wilson, Arun J Sanyal, Velimir A Luketic, R Todd Stravitz, Melissa J Contos, A Scott Mills, Mitchell L Shiffman.   

Abstract

BACKGROUND & AIMS: Hepatitis C virus (HCV) coinfection is common in patients with human immunodeficiency virus (HIV) infection. The mortality associated with HIV has decreased dramatically with the introduction of highly active antiretroviral therapy (HAART). However, the impact of HAART, including protease inhibitors (PIs), nucleoside reverse-transcriptase inhibitors (NRTIs), and non-NRTIs (NNRTIs), on the spectrum of HCV-related liver disease remains unclear. The purpose of this retrospective analysis is to determine the impact of PI and NNRTI use on liver histological characteristics in patients with stable HIV-HCV coinfection (n = 101) compared with HIV-uninfected controls with HCV infection (n = 302).
METHODS: The majority of coinfected patients were men (75%), African American (82%), and had genotype 1 HCV (91%). Mean HIV load was 1.52 log copies/mL, 48% had undetectable HIV RNA and a mean CD4 count of 528 cells/microL, and 11% had a CD4 count < 200 cells/microL. Both mean alanine aminotransferase (ALT) level (83 U/L; 54% had a normal ALT level) and Knodell Histological Activity Index score (7.04; 33% had advanced fibrosis) were similar to those of our control population. Ninety-three percent of patients were administered a mean of 3 antiretroviral medications: NRTIs in 98%, NNRTIs in 45%, and PIs in 54%.
RESULTS: There were no significant differences in biochemical or histological parameters between patients administered or not administered PIs or NNRTIs.
CONCLUSIONS: In this uncontrolled retrospective analysis, we were unable to show a significant impact of either PI or NNRTI use on the spectrum of liver disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15118983     DOI: 10.1016/s1542-3565(04)00129-6

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  8 in total

1.  Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samples.

Authors:  Richard K Sterling; Jacob A Wegelin; Paula G Smith; R Todd Stravitz; Velimir A Luketic; Michael Fuchs; Puneet Puri; Mitchell L Shiffman; Melissa A Contos; A Scott Mills; Arun J Sanyal
Journal:  Clin Gastroenterol Hepatol       Date:  2010-08-20       Impact factor: 11.382

2.  HIV variability in the liver and evidence of possible compartmentalization.

Authors:  Jason T Blackard; Gang Ma; Christina M Martin; Susan D Rouster; M Tarek Shata; Kenneth E Sherman
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-04       Impact factor: 2.205

3.  HIV-HCV Coinfection.

Authors:  Amrita Sethi; Richard K Sterling
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-05

4.  HIV mono-infection is associated with FIB-4 - A noninvasive index of liver fibrosis - in women.

Authors:  Jason T Blackard; Jeffrey A Welge; Lynn E Taylor; Kenneth H Mayer; Robert S Klein; David D Celentano; Denise J Jamieson; Lytt Gardner; Kenneth E Sherman
Journal:  Clin Infect Dis       Date:  2011-01-19       Impact factor: 9.079

Review 5.  Antiviral drugs and the treatment of hepatitis C.

Authors:  Ziba Jalali; Jürgen K Rockstroh
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

6.  Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT.

Authors:  Amy G Shah; Paula G Smith; Richard K Sterling
Journal:  Dig Dis Sci       Date:  2011-04-28       Impact factor: 3.199

7.  Low-level HIV infection of hepatocytes.

Authors:  Ling Kong; Walter Cardona Maya; Maria E Moreno-Fernandez; Gang Ma; Mohamed T Shata; Kenneth E Sherman; Claire Chougnet; Jason T Blackard
Journal:  Virol J       Date:  2012-08-09       Impact factor: 4.099

8.  HIV infection of hepatocytes results in a modest increase in hepatitis C virus expression in vitro.

Authors:  Ling Kong; Jeffrey A Welge; Eleanor A Powell; Jason T Blackard
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.